Literature DB >> 9835324

Effect of interferon gamma on intrahepatic haemodynamics of the cirrhotic rat liver.

H J Grossman1, D White, V L Grossman, P S Bhathal.   

Abstract

Sublethal injury of the liver with carbon tetrachloride (CCl4) induces the modulation of hepatic stellate cells to their myofibroblast (MFB) phenotype. Pretreatment or concomitant treatment with interferon gamma (IFNgamma) has been shown to inhibit this phenomenon. The aim of this study was to investigate the influence of IFNgamma treatment (50000 IU s.c. each day for 5 days) in rats with an established cirrhosis. Cirrhosis was induced with nine doses of CCl4. Comparison of biopsies before and after treatment with IFNgamma showed that the number of MFB present, identified by their alpha-smooth muscle actin immunoreactivity, was markedly reduced. Pressure-flow curves were constructed in isolated perfused liver preparations from IFNgamma-treated and saline-treated cirrhotic rats and analysed to obtain the extrapolated zero-flow intercept (Po, an index of hepatic vascular distensibility) and the vasodilator-induced change in resistance at a flow rate of 1 mL/min per g (deltaR1, an indication of the level of intrinsic vascular tone). In IFNgamma-treated rats, portal venous pressure measured in vivo was significantly reduced compared with controls (11.9+/-1.2 vs 16.0+/-0.5 mmHg, P< 0.05), Po was lower (2.03+/-0.18 vs 2.87+/-0.32 mmHg, P<0.05) and deltaR1 was decreased (0.39+/-0.15 vs 1.02+/-0.19 mmHg/mL per min per g, P< 0.05). The findings indicate that treatment with IFNgamma is effective in reducing MFB density in established CCl4-cirrhosis in the rat and results in a marked improvement in intrahepatic haemodynamics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9835324     DOI: 10.1111/j.1440-1746.1998.tb00570.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  3 in total

1.  Type 1 Innate Lymphoid Cells Protect Mice from Acute Liver Injury via Interferon-γ Secretion for Upregulating Bcl-xL Expression in Hepatocytes.

Authors:  Tsukasa Nabekura; Luke Riggan; Andrew D Hildreth; Timothy E O'Sullivan; Akira Shibuya
Journal:  Immunity       Date:  2019-12-03       Impact factor: 31.745

Review 2.  Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?

Authors:  A K Burroughs; R Groszmann; J Bosch; N Grace; G Garcia-Tsao; D Patch; J C Garcia-Pagan; L Dagher
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

3.  Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.

Authors:  Ping Liu; Yi-Yang Hu; Cheng Liu; Da-Yuan Zhu; Hui-Ming Xue; Zhi-Qiang Xu; Lie-Ming Xu; Cheng-Hai Liu; Hong-Tu Gu; Zhi-Qing Zhang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.